Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $392,932.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 4,600 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $85.42, for a total transaction of $392,932.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.37, for a total transaction of $631,738.00.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $85.40 on Friday. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $103.00. The stock has a market cap of $6.97 billion, a P/E ratio of -23.21 and a beta of 2.28. The company has a 50-day moving average of $81.57 and a two-hundred day moving average of $72.16.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same quarter in the prior year, the company earned ($0.88) earnings per share. The firm’s revenue for the quarter was down 60.8% compared to the same quarter last year. As a group, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KYMR. Baker BROS. Advisors LP boosted its holdings in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC grew its position in shares of Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. increased its stake in Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares during the last quarter. Finally, Holocene Advisors LP purchased a new position in Kymera Therapeutics during the third quarter worth about $47,563,000.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KYMR. BTIG Research dropped their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. JPMorgan Chase & Co. increased their price objective on Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Jefferies Financial Group started coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective for the company. Mizuho boosted their target price on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. Finally, Oppenheimer upped their target price on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.90.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Multiple research firms have raised price targets and reiterated buy/outperform views (Mizuho, Oppenheimer, B. Riley, Leerink, UBS), supporting upside expectations for KYMR. Analyst Upgrades and Targets
• Positive Sentiment: Large institutional holders (Baker Bros., Avoro, Vanguard, Price T. Rowe, BVF) increased positions in recent quarters, signaling continued fund-level conviction in Kymera’s Pegasus degrader platform and pipeline. Institutional Activity
• Neutral Sentiment: Company fundamentals/context: Kymera is a clinical‑stage degrader-focused biotech with a mixed near‑term financial picture (recent quarter missed revenue and EPS estimates). These operational results remain a material background factor for how investors value upcoming clinical and partnership milestones. Earnings and Company Profile
• Negative Sentiment: Director Elena Ridloff sold 4,600 shares on April 1 at an average price of ~$85.42 (disclosed via SEC). Large director sales can create near-term selling pressure or signal personal liquidity needs. Ridloff sale (AmericanBankingNews)
• Negative Sentiment: Additional disclosures show Ridloff sold 7,400 shares on March 31 and the April 1 sale was also filed with the SEC. Total recent Ridloff sales amount to ~12,000 shares across the two trades. Ridloff SEC filing
• Negative Sentiment: COO Jeremy G. Chadwick disclosed multiple sales (7,600 on March 31 and 14,640 on April 1) totaling ~22,240 shares at ~\$85.4 average — a roughly double‑digit percentage reduction in his reported ownership. Senior‑exec selling of this size can weigh on sentiment. Chadwick SEC filing
• Negative Sentiment: Multiple independent reports aggregated these insider trades (InsiderTrades, MarketBeat), increasing transparency but also spotlighting the concentration of recent insider liquidity. InsiderTrades summary

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.